SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q {X} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 1996 Commission File No. 0-19131 MEDIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 52-1555759 (State or other jurisdiction of (I. R. S. Employer incorporation or organization) Identification No.) 35 West Watkins Mill Road, Gaithersburg, MD 20878 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (301)417-0770 Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] As of September 30, 1996, 21,656,918 shares of Common Stock, par value $0.01 per share, were outstanding. MEDIMMUNE, INC. Index to Form 10-Q Part I Financial Page Item 1. Financial Statements Balance Sheets 1 Statements of Operations 2 Condensed Statements of Cash Flows 3 Notes to Financial Statements 4 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 5-8 Part II Other Information 8-10 Item 1. Legal Proceedings Item 2. Changes in Securities Item 3. Defaults upon Senior Securities Item 4. Submission of Matters to a Vote of Security Holders Item 5. Other Information Item 6. Exhibits and Reports on Form 8-K CytoGam is a registered trademark and RespiGam is a trademark of the Company. ITEM 1. FINANCIAL STATEMENTS MEDIMMUNE, INC. BALANCE SHEETS (in thousands, except share data) September 30, December 31, 1996 1995 ---------- ---------- ASSETS: (Unaudited) Cash and cash equivalents $ 3,364 $14,165 Marketable securities 120,648 23,874 Trade and contract receivables, net 7,080 3,919 Inventory, net 7,652 6,027 Other current assets 1,002 1,005 ---------- ---------- Total Current Assets 139,746 48,990 Property and equipment, net 18,807 8,255 Other assets 2,138 87 ---------- ---------- Total Assets $160,691 $57,332 ========== ========== LIABILITIES AND SHAREHOLDERS' EQUITY: Accounts payable $2,614 $2,318 Accrued expenses 8,147 6,538 Product royalties payable 991 1,776 Accrued interest payable 975 -- Other current liabilities 115 111 ---------- ---------- Total Current Liabilities 12,842 10,743 Long term debt 63,328 1,984 Other liabilities 978 826 ---------- ---------- Total Liabilities 77,148 13,553 ---------- ---------- Commitments and Contingencies SHAREHOLDERS' EQUITY: Preferred stock, $.01 par value; -- -- authorized 5,524,525 shares; none issued or outstanding Common stock, $.01 par value; 217 177 authorized 60,000,000 shares; issued and outstanding 21,656,918 at September 30, 1996 and 17,706,137 at December 31, 1995 Paid-in capital 171,929 113,435 Accumulated deficit (88,603) (69,833) ---------- ---------- Total Shareholders' Equity 83,543 43,779 ---------- ---------- Total Liabilities and $160,691 $57,332 Shareholders' Equity ========== ========== The accompanying notes are an integral part of these financial statements PAGE (1) MEDIMMUNE, INC STATEMENTS OF OPERATIONS (in thousands except per share data) For the three months For the nine months ended ended September 30, September 30, 1996 1995 1996 1995 -------- -------- -------- -------- REVENUES: Product Sales $4,632 $3,821 $18,086 $11,121 Contracts 148 2,843 5,055 9,330 -------- -------- -------- -------- Total revenues 4,780 6,664 23,141 20,451 -------- -------- -------- -------- COSTS AND EXPENSES: Cost of sales 2,924 2,295 11,046 7,763 Research and development 7,817 5,965 20,059 20,524 Selling, administrative 5,043 2,511 13,602 7,169 and general -------- -------- -------- -------- Total expenses 15,784 10,771 44,707 35,456 -------- -------- -------- -------- Operating Loss (11,004) (4,107) (21,566) (15,005) Interest income 1,806 423 3,880 1,112 Interest expense (964) (62) (1,084) (188) -------- -------- -------- -------- Net Loss ($10,162) ($3,746) ($18,770) ($14,081) ======== ======== ======== ======== Loss Per Common Share ($0.47) ($0.22) ($0.90) ($0.90) ======== ======== ======== ======== Shares Used in Computing Loss Per Share 21,656 16,722 20,782 15,600 ======== ======== ======== ======== The accompanying notes are an integral part of these financial statements PAGE (2) MEDIMMUNE, INC. CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) (in thousands) For the nine months ended September 30, 1996 1995 -------- --------- CASH FLOWS FROM OPERATING ACTIVITIES: Net loss ($18,770) ($14,081) Noncash items: Depreciation and amortization 1,337 1,158 Amortization of discount on (494) (372) marketable securities Allowance for bad debt 739 -- Other changes in assets and liabilities (5,332) 1,581 -------- --------- Net cash used in operating activities (22,520) (11,714) CASH FLOWS FROM INVESTING ACTIVITIES: Increase in marketable securities (96,280) (3,341) Capital expenditures (11,889) (775) -------- --------- Net cash used in investing activities (108,169) (4,116) -------- --------- CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of common 58,534 17,214 stock and exercise of stock options Increase (decrease) in long term debt 61,354 (70) -------- --------- Net cash provided by financing 119,888 17,144 activities -------- -------- Net (decrease) increase in cash and cash (10,801) 1,314 equivalents -------- --------- Cash and cash equivalents at beginning 14,165 6,350 of period -------- --------- Cash and cash equivalents at end of period $3,364 $7,644 ======== ========= The accompanying notes are an integral part of these financial statements. Page (3) NOTES TO FINANCIAL STATEMENTS (UNAUDITED) General The financial information presented as of September 30, 1996 and 1995, and for the periods then ended is unaudited, but in the opinion of the Company's management contains all adjustments (which consist only of normal recurring adjustments) necessary for a fair presentation of such financial information. Inventory Inventory is comprised of the following (in thousands): September 30, December 31, 1996 1995 ------------ --------------- Raw Materials $2,048 $2,193 Work in Process 2,417 2,510 Finished Goods 3,187 1,324 ------ ------ $7,652 $6,027 ====== ====== PROPERTY AND EQUIPMENT Property and equipment at September 30 includes $0.1 million of capitalized interest related to the design and construction of the Company's manufacturing facility and expansion of its pilot plant. Page (4) ITEM 2. MEDIMMUNE, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS RESULTS OF OPERATIONS THREE MONTHS ENDED SEPTEMBER 30, 1996 AND 1995 Product sales grew to $4.6 million in third quarter 1996 from $3.8 million in third quarter 1995, an increase of 21%. CytoGam sales increased 28% to $4.9 million, primarily as a result of a 25% increase in vials sold, as well as a price increase which took effect in mid-1996. Sales of the Company's second product, RespiGam, approved for marketing by the U. S. Food and Drug Administration ("FDA") on January 18, 1996, were $0.5 million for the three months. Sales of RespiGam are expected principally during the RSV season which typically occurs from November through April. In addition, a charge of $0.7 million was recorded against product sales for trade receivables due from a pharmaceutical wholesaler, which filed for Chapter 11 bankruptcy in August 1996. Contract revenue in the 1996 third quarter decreased to $0.1 million from $2.8 million in the 1995 quarter, reflecting the completion of milestone and research funding payments under the Company's strategic alliance with American Home Products ("AHP"), formerly American Cyanamid Company. Under the terms of the alliance, the Company and AHP will share in the profits or losses of RespiGam, reimbursements or payments under this arrangement are deducted from or added to operating expenses. Cost of sales increased to $2.9 million in third quarter 1996 from $2.3 million in third quarter 1995, an increase of 27%. This increase was primarily attributable to a 25% increase in unit volume for CytoGam and the addition of cost of sales for RespiGam, offset by a reduction in the royalty paid on CytoGam sales in the 1996 period as a result of an amendment to the agreement with Connaught Laboratories, Inc. ("Connaught"). Cost of sales was also reduced by a $0.3 million credit for RespiGam inventory written off in first quarter 1996 that is now expected to be available for sale in the fourth quarter. Research and development spending increased 31% to $7.8 million in this year's quarter compared to $6.0 million in the 1995 quarter. Research and development expenses incurred in 1996 include costs of conducting the Company's MEDI-493 (RSV monoclonal antibody) and MEDI-500 (T10B9) clinical trials, while 1995 expenses included the costs of completing RespiGam Phase 3 clinical trials. Selling, administrative and general expenses increased to $5.0 million in this year's quarter versus $2.5 million in the 1995 third quarter, an increase of 101%. This increase was primarily a result of marketing expenses incurred for RespiGam and expenses Page 5 associated with the expanded sales force, partially offset by reimbursement from AHP of its share of RespiGam product line loss for the quarter, as well as a $0.2 million increase in general and administrative expenses. Interest income of $1.8 million was earned in the 1996 third quarter, compared to $0.4 million in the third quarter of 1995, reflecting higher cash balances available for investment, as a result of the debt and equity offerings in 1996. This was partially offset by a decrease in interest rates which lowered the overall portfolio yield. Interest expense of $1.0 million was incurred in the 1996 quarter versus $0.1 million in the 1995 quarter reflecting interest due on the convertible subordinated notes that were issued July 8, 1996. The net loss incurred in the 1996 third quarter of $10.2 million, or $.47 per common share, compared to a net loss for the third quarter of 1995 of $3.7 million, or $.22 per common share. Shares used in computing loss per share were 21.7 million and 16.7 million for the 1996 and 1995 quarters, respectively. These results were consistent with the Company's objectives for the quarter and with the continued development of its immunotherapeutic and vaccine products. Quarterly financial results may vary significantly due to seasonality of RespiGam product sales, fluctuation in sales of CytoGam, research funding and expenditures for research, development and marketing programs. RespiGam sales are expected to occur primarily during, and in proximity to, the RSV season, which typically occurs between November and April in the United States. In the fourth quarter of 1996, the Company anticipates substantial increases in research and development expenses, primarily reflecting costs of the MEDI-493 clinical trial program as well as increased sales and marketing expenses for RespiGam. Raw material supply as well as production capacity may impose constraints on finished product availability of CytoGam and RespiGam. NINE MONTHS ENDED SEPTEMBER 30, 1996 AND 1995 Product sales for the nine months ended September 30, 1996 increased 63% to $18.1 million compared to $11.1 million in the 1995 period. Sales of CytoGam increased 38% to $15.3 million in this year's period from $11.1 million in the 1995 period, reflecting a 33% increase in units sold as well two price increases since mid-1995. RespiGam sales were $3.5 million in the 1996 period following receipt of marketing approval from the FDA on January 18, 1996. Product sales were reduced by a $0.7 million charge in the 1996 third quarter for trade receivables due from a pharmaceutical wholesaler which filed Chapter 11 bankruptcy in August 1996. Contract revenue in the 1996 nine Page (6) months decreased to $5.1 million from $9.3 million in the 1995 period, primarily reflecting funding provided under the Company's strategic alliance with American Home Products. Cost of sales in the 1996 period rose to $11.0 million from $7.8 million in the 1995 period, reflecting a 33% increase in unit volume of CytoGam and the addition of cost of sales for RespiGam. Cost of sales for both periods include the purchase of certain finished product inventory from a third party at a higher per- unit cost in order to meet product demand due to supply shortages. Research and development spending was relatively flat at $20.1 million in this year's nine months versus $20.5 million in the 1995 period. Expenses in the 1996 period include the costs of conducting MEDI-493 (RSV monoclonal antibody) and MEDI- 500 (T10B9) clinical trials. Expenses in the 1995 period included the costs of Phase 3 RespiGam clinical trials. Selling, administrative and general expenses increased to $13.6 million in the 1996 nine months versus $7.2 million in the 1995 period primarily reflecting costs of marketing RespiGam and the expansion of the sales force, partially offset by AHP reimbursement of their share of RespiGam product line loss. Administrative expenses for the 1996 period include charges of $0.8 million associated with the Company's manufacturing facility. Interest income of $3.9 million was earned in the 1996 nine months, compared to $1.1 million in the 1995 period, reflecting higher cash balances available for investment, partially offset by a decrease in interest rates which lowered the overall portfolio yield. Interest expense of $1.1 million was incurred in the 1996 period versus $0.2 million in the 1995 period. This increase primarily reflects the first quarter of interest due on the Company's convertible subordinated notes. The net loss incurred in the 1996 period of $18.8 million, or $.90 per common share, compared to a net loss for the 1995 period of $14.1 million, or $.90 per common share. Shares used in computing loss per share were 20.8 million and 15.6 million for the nine months ending 1996 and 1995, respectively. LIQUIDITY AND CAPITAL RESOURCES Cash and marketable securities at September 30, 1996 were $124.0 million compared to $38.0 million at 1995 year end. Net cash used in operating activities in the nine months ended September 30, 1996 was $22.5 million, reflecting primarily the net loss for the period, an increase in trade and contract receivables, and a $2.7 million contractual payment to Connaught, offset by increased accrued expenses, including primarily clinical trial costs. Capital expenditures of $11.9 million for Page (7) the nine months were primarily for design and construction of a new manufacturing facility and for lab equipment. The Company expects to invest approximately $56 million in expansion of its pilot plant facility and on construction of a manufacturing facility during 1996 and 1997. In February 1996, the Company completed a public offering of 3.45 million shares of common stock resulting in net proceeds of $58 million. Additionally, on July 8, 1996, the Company completed an offering of $60 million aggregate principal amount of 7% convertible subordinated notes due 2003 for net proceeds of $58 million. Proceeds of the note offering will be used for general corporate purposes, including funding capital expenditures associated with the construction of the Company's new manufacturing facility and expansion of its pilot plant. ____________________ THE STATEMENTS IN THIS QUARTERLY REPORT THAT ARE NOT DESCRIPTIONS OF HISTORICAL FACTS MAY BE FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS REFLECT MANAGEMENT'S CURRENT VIEWS, ARE BASED ON CERTAIN ASSUMPTIONS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES, INCLUDING BUT NOT LIMITED TO, FACTORS SUCH AS PRODUCT DEMAND AND MARKET ACCEPTANCE RISKS, THE EARLY STAGE OF PRODUCT DEVELOPMENT, COMMERCIALIZATION AND TECHNOLOGICAL DIFFICULTIES, CAPACITY AND SUPPLY CONSTRAINTS AND OTHER RISKS DETAILED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE CURRENTLY ANTICIPATED AS A RESULT OF THE FOREGOING OR OTHER FACTORS. PART II OTHER INFORMATION Item 1. Legal Proceedings - None Item 2. Changes in Securities - None Item 3. Defaults upon Senior Securities - None Item 4. Submission of Matters to a Vote of Security Holders: On May 14, 1996 the Company held its Annual Meeting of Stockholders. By vote of the Company's stockholders at such meeting, all of the director nominees were re-elected to one-year terms and the appointment of Coopers & Lybrand L.L.P. as the Company's independent auditors was approved. The results of the voting was as follows: Page (8) Election of Directors Abstain/ For Against Withheld Non-vote Wayne T. Hockmeyer 16,131,115 -- * -- David M. Mott 16,131,115 -- * -- Franklin H. Top, Jr. 16,131,115 -- * -- M. James Barrett 16,131,115 -- * -- James H. Cavanaugh 16,131,115 -- * -- Barbara Hackman Franklin 16,131,115 -- * -- Lawrence C. Hoff 16,131,115 -- * -- Gordon S. Macklin 16,131,115 -- * -- * Only a minor number of votes withheld authority to vote for various individual directors, the highest as to any one director being 57,155. Appointment of Independent Auditors Coopers & Lybrand L.L.P. 16,154,765 25,855 -- 7,650 On August 5, 1996, the Company held a special meeting of Stockholders. By vote of the Company's stockholders at such meeting, an amendment to the Company's Restated Certificate of Incorporation increasing the number of shares of Common Stock that the Company is authorized to issue to 60,000,000 from 30,000,000 was approved. The results of the voting were as follows: Abstain/ For Against Withheld Non-vote 18,697,130 1,077,001 -- 30,680 Item 5. Other Information - None Item 6. Exhibits and Reports on Form 8-K (a) Exhibits: None (b) Reports on Form 8-K: Report Date Event reported 6/26/96 MedImmune In-License Key Human Papillomavirus Vaccine Intellectual Property from German Cancer Research Center Page (9) 7/2/96 MedImmune Submits Application for Approval of RespiGam in Canada MedImmune Places $60 Million in 7% Convertible Subordinated Notes - Transaction Expected to Close July 8, 1996 7/25/96 MedImmune Reports Record Product Sales 8/12/96 MedImmune Announces Facility Expansion in Maryland SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MEDIMMUNE, INC. (Registrant) Date: November 14, 1996 /s/David M. Mott President and Chief Operating Officer (Principal accounting and financial officer) Page (10)